ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

June 14, 2023

Study Completion Date

July 14, 2023

Conditions
Breast Surgery
Interventions
DRUG

Ropivacaïne Hydrochloride by Erector Spinae block

Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.

DRUG

Ropivacaïne Hydrochloride by Paravertebral block

Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.

Trial Locations (5)

31059

Institut Claudius Régaud UICT, Toulouse

54500

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

63000

Centre Jean Perrin, Clermont-Ferrand

75970

AP-HP Hôpital Tenon, Paris

92210

Institut Curie, Saint-Cloud

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

lead

Institut Curie

OTHER